Wall Street analysts forecast that CryoPort Inc (NASDAQ:CYRX) will report sales of $9.50 million for the current quarter, Zacks reports. Five analysts have made estimates for CryoPort’s earnings, with estimates ranging from $9.40 million to $9.65 million. CryoPort posted sales of $5.29 million during the same quarter last year, which would indicate a positive year over year growth rate of 79.6%. The company is scheduled to issue its next earnings report on Thursday, November 14th.
According to Zacks, analysts expect that CryoPort will report full-year sales of $35.04 million for the current year, with estimates ranging from $34.50 million to $35.58 million. For the next fiscal year, analysts forecast that the firm will report sales of $52.51 million, with estimates ranging from $47.50 million to $58.53 million. Zacks’ sales calculations are an average based on a survey of research firms that cover CryoPort.
CryoPort (NASDAQ:CYRX) last issued its earnings results on Thursday, August 8th. The consumer goods maker reported ($0.08) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). CryoPort had a negative net margin of 35.71% and a negative return on equity of 17.32%. The company had revenue of $8.46 million for the quarter, compared to analysts’ expectations of $7.94 million. During the same period in the prior year, the business earned ($0.09) EPS. The firm’s quarterly revenue was up 82.7% on a year-over-year basis.
A number of institutional investors have recently added to or reduced their stakes in the stock. D. E. Shaw & Co. Inc. grew its stake in CryoPort by 1.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 48,429 shares of the consumer goods maker’s stock valued at $887,000 after acquiring an additional 783 shares during the period. Northern Trust Corp boosted its stake in CryoPort by 0.3% during the 4th quarter. Northern Trust Corp now owns 338,111 shares of the consumer goods maker’s stock worth $3,729,000 after purchasing an additional 1,028 shares during the last quarter. Rhumbline Advisers boosted its stake in CryoPort by 3.1% during the 1st quarter. Rhumbline Advisers now owns 34,962 shares of the consumer goods maker’s stock worth $452,000 after purchasing an additional 1,043 shares during the last quarter. Greenwood Capital Associates LLC boosted its stake in CryoPort by 5.8% during the 2nd quarter. Greenwood Capital Associates LLC now owns 20,014 shares of the consumer goods maker’s stock worth $367,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in CryoPort by 2.2% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 64,566 shares of the consumer goods maker’s stock worth $1,183,000 after purchasing an additional 1,402 shares during the last quarter. 47.41% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:CYRX traded up $0.18 during trading on Tuesday, reaching $22.01. The stock had a trading volume of 52,920 shares, compared to its average volume of 500,987. CryoPort has a one year low of $8.28 and a one year high of $25.02. The company has a market capitalization of $779.13 million, a P/E ratio of -71.03 and a beta of 0.82. The company has a current ratio of 17.73, a quick ratio of 17.68 and a debt-to-equity ratio of 0.17. The firm’s 50-day simple moving average is $21.11 and its 200 day simple moving average is $16.26.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Read More: What are Institutional Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.